

preventing infections in healthcare settings. The guideline replaces the Guideline for Prevention of Nosocomial Pneumonia, published in 1994.

**DATES:** Comments on the Draft Guideline for Prevention of Healthcare-associated Pneumonia, 2003, must be received in writing on or before October 18, 2002.

**FOR FURTHER INFORMATION CONTACT:**

Requests for copies of the Draft Guideline for Prevention of Healthcare-associated Pneumonia, 2003, should be submitted to the Resource Center, Attention: PNGuide, Division of Healthcare Quality Promotion, CDC, Mailstop E-68, 1600 Clifton Rd., NE, Atlanta, Georgia 30333; fax 404 498-1244; e-mail: [pnrequests@cdc.gov](mailto:pnrequests@cdc.gov); or Internet: [www.cdc.gov/ncidod/hip/pnguide.htm](http://www.cdc.gov/ncidod/hip/pnguide.htm).

**ADDRESSES:** Comments on the Draft Guideline for Prevention of Healthcare-associated Pneumonia, 2003, should be submitted to the Resource Center, Attention: PNGuide, Division of Healthcare Quality Promotion, CDC, Mailstop E-68, 1600 Clifton Road, NE, Atlanta, Georgia 30333; fax 404 498-1244; e-mail: [pncomments@cdc.gov](mailto:pncomments@cdc.gov); or Internet: [www.cdc.gov/ncidod/hip/pnguide.htm](http://www.cdc.gov/ncidod/hip/pnguide.htm).

**SUPPLEMENTARY INFORMATION:** The Draft Guideline for Prevention of Healthcare-associated Pneumonia, 2003, addresses the prevention and control of healthcare-associated bacterial pneumonia, especially ventilator-associated pneumonia; Legionnaire's disease; pertussis; invasive pulmonary aspergillosis; viral pneumonia; respiratory syncytial virus infection; parainfluenza; adenovirus infection; and influenza. Part I discusses the epidemiology, diagnosis, pathogenesis, modes of transmission, and prevention and control of the diseases listed above. Part II contains the consensus recommendations of the Healthcare Infection Control Practices Advisory Committee (HICPAC) and addresses such issues as education of healthcare personnel regarding the prevention and control of healthcare-associated pneumonia and other lower respiratory tract diseases and measures to prevent person-to-person transmission of each disease.

HICPAC was established in 1991 to provide advice and guidance to the Secretary and the Assistant Secretary for Health, DHHS; the Director, CDC; and the Director, National Center for Infectious Diseases, regarding the practice of infection control and strategies for surveillance, prevention, and control of healthcare-associated

infections in U.S. healthcare facilities. The committee advises CDC on guidelines and other policy statements regarding prevention of healthcare-associated infections and related adverse events.

Dated: August 27, 2002.

**James D. Seligman,**

*Associate Director for Program Services,  
Centers for Disease Control and Prevention.*

[FR Doc. 02-22309 Filed 8-30-02; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Administration for Children and Families

#### President's Committee on Mental Retardation; Notice of Meeting

**AGENCY:** President's Committee on Mental Retardation (PCMR).

**ACTION:** Notice of meeting.

**DATES:** Monday, September 23, 2002, from 8 a.m. to 5 p.m., and Tuesday, September 24, 2002, from 8 a.m. to 11 a.m. The entire meeting of the President's Committee on Mental Retardation will be open to the public.

**ADDRESSES:** The meeting will be held at the Indian Treaty Room, Old Executive Office Building, 17th Street and Pennsylvania Avenue, Washington, DC 20500. Enter the building at the Pennsylvania Avenue entrance and be prepared to show a photo ID. Please allow extra time for security procedures. It will be necessary for all persons planning to enter the Old Executive Office Building to provide their name, date of birth and social security number no later than September 13, 2002, to the Executive Director, President's Committee on Mental Retardation (see below for contact information). A barrier free entrance is available to the Old Executive Office Building at its 17th and G Streets, NW., entrance. The same security requirements apply for that entrance.

**Agenda:** The Committee plans to discuss critical issues concerning President George W. Bush's New Freedom Initiative, inter-agency collaboration and cooperation, and removal of barriers to full community integration and improved quality of life for individuals with mental retardation. An interpreter for the deaf will be available upon request.

**FOR FURTHER INFORMATION CONTACT:** Sally Atwater, President's Committee on Mental Retardation, Room 701, Aerospace Building, 370 L'Enfant Promenade, SW., Washington, DC

20447, telephone—(202) 619-0634, fax—(202) 205-9519, e-mail—[satwater@acf.hhs.gov](mailto:satwater@acf.hhs.gov).

**SUPPLEMENTARY INFORMATION:** The PCMR acts in an advisory capacity to the President and the Secretary of the U.S. Department of Health and Human Services on a broad range of topics relating to programs, services and support for persons with mental retardation. The Committee is responsible for evaluating the adequacy of current practices in programs and support for person with mental retardation, and for reviewing legislative proposals that impact the quality of life that is experienced by citizens with mental retardation and their families. The Committee submits an annual report to the President.

Dated: August 26, 2002.

**Sally Atwater,**

*Executive Director, President's Committee on Mental Retardation.*

[FR Doc. 02-22318 Filed 8-30-02; 8:45 am]

**BILLING CODE 4184-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Substance Abuse and Mental Health Services Administration

#### Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies

**AGENCY:** Substance Abuse and Mental Health Services Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Department of Health and Human Services notifies Federal agencies of the laboratories currently certified to meet standards of subpart C of Mandatory Guidelines for Federal Workplace Drug Testing Programs (59 FR 29916, 29925). A notice listing all currently certified laboratories is published in the **Federal Register** during the first week of each month. If any laboratory's certification is suspended or revoked, the laboratory will be omitted from subsequent lists until such time as it is restored to full certification under the Guidelines.

If any laboratory has withdrawn from the National Laboratory Certification Program during the past month, it will be listed at the end, and will be omitted from the monthly listing thereafter.

This notice is also available on the internet at the following websites: <http://workplace.samhsa.gov> and <http://www.drugfreeworkplace.gov>.

**FOR FURTHER INFORMATION CONTACT:** Mrs. Giselle Hersch or Dr. Walter Vogl,

Division of Workplace Programs, 5600 Fishers Lane, Rockwall 2 Building, Room 815, Rockville, Maryland 20857; Tel.: (301) 443-6014, Fax: (301) 443-3031.

#### SUPPLEMENTARY INFORMATION:

Mandatory Guidelines for Federal Workplace Drug Testing were developed in accordance with Executive Order 12564 and section 503 of Public Law 100-71. Subpart C of the Guidelines, "Certification of Laboratories Engaged in Urine Drug Testing for Federal Agencies," sets strict standards which laboratories must meet in order to conduct urine drug testing for Federal agencies. To become certified an applicant laboratory must undergo three rounds of performance testing plus an on-site inspection.

To maintain that certification a laboratory must participate in a quarterly performance testing program plus periodic, on-site inspections.

Laboratories which claim to be in the applicant stage of certification are not to be considered as meeting the minimum requirements expressed in the HHS Guidelines. A laboratory must have its letter of certification from SAMHSA, HHS (formerly: HHS/NIDA) which attests that it has met minimum standards.

In accordance with Subpart C of the Guidelines, the following laboratories meet the minimum standards set forth in the Guidelines:

ACL Laboratories  
8901 W. Lincoln Ave.  
West Allis, WI 53227  
414-328-7840/800-877-7016  
(Formerly: Bayshore Clinical Laboratory)

ACM Medical Laboratory, Inc.  
160 Elmgrove Park  
Rochester, NY 14624  
716-429-2264

Advanced Toxicology Network  
3560 Air Center Cove, Suite 101  
Memphis, TN 38118  
901-794-5770/888-290-1150

Aegis Analytical Laboratories, Inc.  
345 Hill Ave.  
Nashville, TN 37210  
615-255-2400

Alliance Laboratory Services  
3200 Burnet Ave.  
Cincinnati, OH 45229  
513-585-9000  
(Formerly: Jewish Hospital of Cincinnati, Inc.)

American Medical Laboratories, Inc.  
14225 Newbrook Dr.  
Chantilly, VA 20151  
703-802-6900

Associated Pathologists Laboratories, Inc.  
4230 South Burnham Ave., Suite 250  
Las Vegas, NV 89119-5412  
702-733-7866/800-433-2750

Baptist Medical Center—Toxicology Laboratory

9601 I-630, Exit 7  
Little Rock, AR 72205-7299  
501-202-2783  
(Formerly: Forensic Toxicology Laboratory Baptist Medical Center)

Clinical Laboratory Partners, LLC  
129 East Cedar St.  
Newington, CT 06111  
860-696-8115  
(Formerly: Hartford Hospital Toxicology Laboratory)

Clinical Reference Lab  
8433 Quivira Rd.  
Lenexa, KS 66215-2802  
800-445-6917

Cox Health Systems, Department of Toxicology  
1423 North Jefferson Ave.  
Springfield, MO 65802  
800-876-3652/417-269-3093  
(Formerly: Cox Medical Centers)

Diagnostic Services Inc., dba DSI  
12700 Westlinks Drive  
Fort Myers, FL 33913  
941-561-8200/800-735-5416

Doctors Laboratory, Inc.  
P.O. Box 2658, 2906 Julia Dr.  
Valdosta, GA 31602  
912-244-4468

DrugProof, Division of Dynacare  
543 South Hull St.  
Montgomery, AL 36103  
888-777-9497/334-241-0522  
(Formerly: Alabama Reference Laboratories, Inc.)

DrugProof, Division of Dynacare/Laboratory of Pathology, LLC  
1229 Madison St., Suite 500, Nordstrom Medical Tower  
Seattle, WA 98104  
206-386-2672/800-898-0180  
(Formerly: Laboratory of Pathology of Seattle, Inc., DrugProof, Division of Laboratory of Pathology of Seattle, Inc.)

DrugScan, Inc.  
P.O. Box 2969, 1119 Mearns Rd.  
Warminster, PA 18974  
215-674-9310

Dynacare Kasper Medical Laboratories \*  
14940-123 Ave.,  
Edmonton, Alberta  
Canada T5V 1B4  
780-451-3702/800-661-9876

ElSohly Laboratories, Inc.  
5 Industrial Park Dr.  
Oxford, MS 38655  
662-236-2609

Express Analytical Labs  
3405 7th Avenue, Suite 106  
Marion, IA 52302  
319-377-0500

Gamma-Dynacare Medical Laboratories \*  
A Division of the Gamma-Dynacare Laboratory Partnership  
245 Pall Mall St.  
London, ONT  
Canada N6A 1P4  
519-679-1630

General Medical Laboratories  
36 South Brooks St.  
Madison, WI 53715  
608-267-6267

Kroll Laboratory Specialists, Inc.

1111 Newton St.  
Gretna, LA 70053  
504-361-8989/800-433-3823  
(Formerly: Laboratory Specialists, Inc.)

LabOne, Inc.  
10101 Renner Blvd.  
Lenexa, KS 66219  
913-888-3927/800-728-4064  
(Formerly: Center for Laboratory Services, a Division of LabOne, Inc.)

Laboratory Corporation of America Holdings  
7207 N. Gessner Road  
Houston, TX 77040  
713-856-8288/800-800-2387

Laboratory Corporation of America Holdings  
69 First Ave.  
Raritan, NJ 08869  
908-526-2400/800-437-4986  
(Formerly: Roche Biomedical Laboratories, Inc.)

Laboratory Corporation of America Holdings  
1904 Alexander Drive  
Research Triangle Park, NC 27709  
919-572-6900/800-833-3984  
(Formerly: LabCorp Occupational Testing Services, Inc., CompuChem Laboratories, Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche Group)

Laboratory Corporation of America Holdings  
10788 Roselle Street  
San Diego, CA 92121  
800-882-7272  
(Formerly: Poisonlab, Inc.)

Laboratory Corporation of America Holdings  
1120 Stateline Road West  
Southaven, MS 38671  
866-827-8042/800-233-6339  
(Formerly: LabCorp Occupational Testing Services, Inc., MedExpress/National Laboratory Center)

Marshfield Laboratories  
Forensic Toxicology Laboratory  
1000 North Oak Ave.  
Marshfield, WI 54449  
715-389-3734/800-331-3734

MAXXAM Analytics Inc. \*  
5540 McAdam Rd.  
Mississauga, ON  
Canada L4Z 1P1  
905-890-2555  
(Formerly: NOVAMANN (Ontario) Inc.)

Medical College Hospitals Toxicology Laboratory, Department of Pathology  
3000 Arlington Ave.  
Toledo, OH 43699  
419-383-5213

MedTox Laboratories, Inc.  
402 W. County Rd. D  
St. Paul, MN 55112  
651-636-7466/800-832-3244

MetroLab-Legacy Laboratory Services  
1225 NE 2nd Ave.  
Portland, OR 97232  
503-413-5295/800-950-5295

Minneapolis Veterans Affairs Medical Center  
Forensic Toxicology Laboratory  
1 Veterans Drive  
Minneapolis, Minnesota 55417  
612-725-2088

National Toxicology Laboratories, Inc.

1100 California Ave.  
Bakersfield, CA 93304  
661-322-4250/800-350-3515

Northwest Drug Testing, a division of NWT Inc.

1141 E. 3900 South  
Salt Lake City, UT 84124  
801-293-2300/800-322-3361  
(Formerly: NWT Drug Testing, NorthWest Toxicology, Inc.)

One Source Toxicology Laboratory, Inc.  
1705 Center Street  
Deer Park, TX 77536  
713-920-2559

(Formerly: University of Texas Medical Branch, Clinical Chemistry Division; UTMB

Pathology-Toxicology Laboratory)

Oregon Medical Laboratories  
P.O. Box 972, 722 East 11th Ave.  
Eugene, OR 97440-0972  
541-687-2134

Pacific Toxicology Laboratories  
6160 Variel Ave.  
Woodland Hills, CA 91367  
818-598-3110/800-328-6942  
(Formerly: Centinela Hospital Airport Toxicology Laboratory)

Pathology Associates Medical Laboratories  
110 West Cliff Drive  
Spokane, WA 99204  
509-755-8991/800-541-7891x8991

PharmChem Laboratories, Inc.  
4600 N. Beach  
Haltom City, TX 76137  
817-605-5300

(Formerly: PharmChem Laboratories, Inc., Texas Division; Harris Medical Laboratory)

Physicians Reference Laboratory  
7800 West 110th St.

Overland Park, KS 66210  
913-339-0372/800-821-3627

Quest Diagnostics Incorporated  
3175 Presidential Dr.  
Atlanta, GA 30340

770-452-1590  
(Formerly: SmithKline Beecham Clinical Laboratories, SmithKline Bio-Science Laboratories)

Quest Diagnostics Incorporated  
4770 Regent Blvd.

Irving, TX 75063  
800-842-6152

(Moved from the Dallas location on 03/31/01; Formerly: SmithKline Beecham Clinical Laboratories, SmithKline Bio-Science Laboratories)

Quest Diagnostics Incorporated  
400 Egypt Rd.  
Norristown, PA 19403

610-631-4600/877-642-2216

(Formerly: SmithKline Beecham Clinical Laboratories, SmithKline Bio-Science Laboratories)

Quest Diagnostics Incorporated  
506 E. State Pkwy.

Schaumburg, IL 60173  
800-669-6995/847-885-2010

(Formerly: SmithKline Beecham Clinical Laboratories, International Toxicology Laboratories)

Quest Diagnostics Incorporated  
7600 Tyrone Ave.

Van Nuys, CA 91405

818-989-2520/800-877-2520  
(Formerly: SmithKline Beecham Clinical Laboratories)

Scientific Testing Laboratories, Inc.  
463 Southlake Blvd.  
Richmond, VA 23236  
804-378-9130

S.E.D. Medical Laboratories  
5601 Office Blvd.  
Albuquerque, NM 87109  
505-727-6300/800-999-5227

South Bend Medical Foundation, Inc.  
530 N. Lafayette Blvd.  
South Bend, IN 46601  
219-234-4176

Southwest Laboratories  
2727 W. Baseline Rd.  
Tempe, AZ 85283  
602-438-8507/800-279-0027

Sparrow Health System  
Toxicology Testing Center, St. Lawrence Campus

1210 W. Saginaw  
Lansing, MI 48915

517-377-0520  
(Formerly: St. Lawrence Hospital & Healthcare System)

St. Anthony Hospital Toxicology Laboratory  
1000 N. Lee St.  
Oklahoma City, OK 73101  
405-272-7052

Sure-test Laboratories, Inc.  
2900 Broad Avenue  
Memphis, Tennessee 38112  
901-474-6028

Toxicology & Drug Monitoring Laboratory  
University of Missouri Hospital & Clinics  
2703 Clark Lane, Suite B, Lower Level  
Columbia, MO 65202  
573-882-1273

Toxicology Testing Service, Inc.  
5426 N.W. 79th Ave.

Miami, FL 33166  
305-593-2260

US Army Forensic Toxicology Drug Testing Laboratory

Fort Meade, Building 2490  
Wilson Street

Fort George G. Meade, MD 20755-5235  
301-677-7085

\* The Standards Council of Canada (SCC) voted to end its Laboratory Accreditation Program for Substance Abuse (LAPSA) effective May 12, 1998. Laboratories certified through that program were accredited to conduct forensic urine drug testing as required by U.S. Department of Transportation (DOT) regulations. As of that date, the certification of those accredited Canadian laboratories will continue under DOT authority. The responsibility for conducting quarterly performance testing plus periodic on-site inspections of those LAPSA-accredited laboratories was transferred to the U.S. DHHS, with the DHHS' National Laboratory Certification Program (NLCP) contractor continuing to have an active role in the performance testing and laboratory inspection processes. Other Canadian laboratories wishing to be considered for the NLCP may apply directly to the NLCP contractor just as U.S. laboratories do.

Upon finding a Canadian laboratory to be qualified, the DHHS will recommend that DOT certify the laboratory (**Federal Register**, 16 July 1996) as meeting the minimum standards of the "Mandatory Guidelines for Workplace Drug Testing" (59 **Federal Register**, 9 June 1994, Pages 29908-29931). After receiving the DOT certification, the laboratory will be included in the monthly list of DHHS certified laboratories and participate in the NLCP certification maintenance program.

**Richard Kopanda,**

*Executive Officer, SAMHSA.*

[FR Doc. 02-22304 Filed 8-30-02; 8:45 am]

**BILLING CODE 4160-20-P**

## DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR-4739-N-41]

### Notice of Submission of Proposed Information Collection to OMB; Emergency Comment Request; Inventory of Housing Units Designated for Elderly/Disabled Persons; Notice of Proposed Information Collection for Public Comment

**AGENCY:** Office of the Assistant Secretary for Housing—Federal Housing Commissioner, HUD.

**ACTION:** Notice.

**SUMMARY:** The proposed information collection requirement described below has been submitted to the Office of Management and Budget (OMB) for emergency review and approval, as required by the Paperwork Reduction Act. The Department is soliciting public comments on the subject proposal.

**DATES:** *Comments Due Date:* September 10, 2002.

**ADDRESSES:** Interested persons are invited to submit comments regarding this proposal. Comments must be received within seven (7) days from the date of this Notice. Comments should refer to the proposal by name/or OMB approval number (2502—pending) and should be sent to: Lauren Wittenberg, HUD Desk Officer, Office of Management and Budget, New Executive Office Building, Washington, DC 20503; Fax number (202) 395-6974; E-mail [Lauren\\_Wittenberg@omb.eop.gov](mailto:Lauren_Wittenberg@omb.eop.gov).

**FOR FURTHER INFORMATION CONTACT:** Wayne Eddins, Reports Management Officer, Department of Housing and Urban Development, 451 Seventh Street, SW., Washington, DC 20410; e-mail [Wayne\\_Eddins@HUD.gov](mailto:Wayne_Eddins@HUD.gov); telephone (202) 708-2374. This is not a toll-free number. Copies of available documents submitted to OMB may be obtained from Mr. Eddins.